Over 20 years of Discovery Research and CMC Operations experience in the discovery & development of multiple first-in-class, disease-modifying therapeutic candidates spanning peptide, biologics, RNA, and small molecule modalities across metabolic disease, hematology/oncology, neurobiology, immunology and inflammation. Track record of fusing science and technology to build and nurture innovative platforms around medicinal, peptide and oligonucleotide chemistry, RNA-based screening, antibody discovery and biologics engineering, structural biology, attribute sciences, pharmacokinetics, laboratory automation, computational chemistry and information technologies. Discovery highlights include AMG 133, an anti-GIPR antibody/GLP-1R agonist multispecific in Phase 2 development, and championing Amgen’s siRNA modality development leading to AMG 890 (olpasiran), RNA silencing Lp(a); currently in Phase 3 development. Additionally, supported the discovery & CMC development of several marketed Amgen products including PARSABIV® etelcalcetide, Aimovig® erenumab, & LUMAKRAS™, sotorasib. The advancement of >30 Research candidates (peptides, oligonucleotides, small molecules, hybrids, antibody drug conjugates, mAbs, multi-specifics, & T-cell engagers) through technical-readiness governance; the filing of >20 Investigational New Drug (IND) applications to advance life-changing medicines for patients.